Next Article in Journal
Free Radical Scavenging and Cellular Antioxidant Properties of Astaxanthin
Next Article in Special Issue
Aquaporins in Salivary Glands: From Basic Research to Clinical Applications
Previous Article in Journal
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping
Open AccessReview

Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure

1
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan
2
Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Kenichi Ishibashi
Int. J. Mol. Sci. 2016, 17(1), 105; https://doi.org/10.3390/ijms17010105
Received: 19 December 2015 / Revised: 7 January 2016 / Accepted: 11 January 2016 / Published: 14 January 2016
(This article belongs to the Special Issue Aquaporin)
Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study. View Full-Text
Keywords: heart failure; congestion; chronic kidney disease; hyponatremia heart failure; congestion; chronic kidney disease; hyponatremia
Show Figures

Graphical abstract

MDPI and ACS Style

Imamura, T.; Kinugawa, K. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. Int. J. Mol. Sci. 2016, 17, 105.

AMA Style

Imamura T, Kinugawa K. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure. International Journal of Molecular Sciences. 2016; 17(1):105.

Chicago/Turabian Style

Imamura, Teruhiko; Kinugawa, Koichiro. 2016. "Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure" Int. J. Mol. Sci. 17, no. 1: 105.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop